Revenue, 2025

USD 412.8 Million

Forecast, 2035

USD 968.32 Million

CAGR, 2026-2035

8.9%

Report Coverage

United States

Key Takeaways for U.S. Endobronchial Ultrasound Biopsy Market

• U.S. endobronchial ultrasound biopsy market to crossed USD 449.54 million by 2026.
• Market projected at USD 968.32 million by 2035.
• CAGR of 8.9% expected in between 2026 to 2035.
• By procedure type, the EBUS-TBNA segment held a dominant revenue share of 58% of the market in 2025.
• By procedure type, the combined EBUS procedures segment held 18% of market share in 2025 and is expected to grow at the fastest CAGR of 11.40% during the forecast period.
• By product type, the EBUS bronchoscopes segment held a dominant revenue share of 39% of the market in 2025.
• By product type, the biopsy needles segment held 27% of market share in 2025 and is expected to grow at the fastest CAGR of 9.6% during the forecast period.
• By application type, the lung cancer diagnosis & staging segment held a dominant revenue share of 49% of the U.S. endobronchial ultrasound biopsy market in 2025.
• By application type, the peripheral pulmonary lesion diagnosis segment held 12% of the market share in 2025 and is expected to grow at the fastest CAGR of 11.80% during the forecast period.
• By end user, the hospitals segment held a dominant position in the market with a share of 62% in 2025.
• By end user, the specialty clinics segment held 17% of the market in 2025 and is expected to grow at the fastest CAGR of 10.60% during the forecast period.

U.S. Endobronchial Ultrasound Biopsy Market Trends for 2026

The U.S. endobronchial ultrasound biopsy market size was estimated at USD 412.8 million in 2025 and is predicted to increase from USD 449.54 million in 2026 to approximately USD 968.32 million by 2035, expanding at a CAGR of 8.9% from 2026 to 2035. The growing lung cancer burden across the U.S. is increasing the demand for endobronchial ultrasound biopsies. Increasing R&D activities, demand for molecular diagnostics, rise in personalized medicines, technological advancements, and new product launches are also enhancing the market growth.

What is the U.S. Endobronchial Ultrasound Biopsy?

The U.S. endobronchial ultrasound biopsy market is driven by a surge in lung cancer screenings and a shift towards minimally invasive diagnostic procedures. The U.S. endobronchial ultrasound biopsy encompasses the devices, accessories, and procedures for endobronchial ultrasound biopsy, driving real-time visualization of lungs, lymph nodes, and airways. It is used for the diagnosis of lung cancer, sarcoidosis, tuberculosis, and enlarged lymph nodes.

What is the Use of AI in the Market?

AI is used in the U.S. endobronchial ultrasound biopsy market for real-time image analysis and early lung cancer diagnosis. It also helps in the detection and characterization of lesions and lymph nodes, as well as personalized treatment planning. AI also helps in automated image interpretation and in the development of robotic bronchoscopy systems.

What are the Major Trends & Future Outlook of the Market?

Expanding Cancer Screening Programs

Increasing cancer prevalence rates in the U.S. are driving their screening programs. This is promoting the use of endobronchial ultrasound biopsy for early and accurate detection of lung cancers.

Rising Molecular Testing Solutions

The growing demand for targeted and personalized cancer treatment drives the use of endobronchial ultrasound biopsy. They are being used for the analysis of high-quality tissue samples for genomic profiling and biomarker analysis.

Escalating Technological Advancements

Expanding technological advancements are driving the development of next-generation EBUS bronchoscopes. Therefore, the companies are developing EBUS bronchoscopes with higher resolution, maneuverability, and enhanced needle guidance systems.

Quick Facts Table

Segmental Insights

By Procedure Type Insights

The EBUS-TBNA Segment Dominated the Market With 58% in 2025

The EBUS-TBNA segment held the largest revenue share of 58% of the U.S. endobronchial ultrasound biopsy market in 2025, due to increased lung cancer staging procedures, which enhanced demand across tertiary hospitals. Minimally invasive sampling also improved physician preference. Favorable reimbursement also supported procedural adoption.

The EBUS-GS segment held the second-largest share of 24% of the market in 2025, driven by the rising diagnosis of peripheral pulmonary lesions, which accelerates their usage. Technological advancements also improve lesion access accuracy. Growing outpatient bronchoscopy volumes also support their expansion.

The combined EBUS procedures segment held 18% of the U.S. endobronchial ultrasound biopsy market share in 2025 and is expected to witness the fastest growth with a CAGR of 11.40% during the forecast period, due to the integration with robotic bronchoscopy, which enhances procedural precision. Complex pulmonary diagnostics also require multimodal navigation systems. Hospitals are also increasingly investing in advanced hybrid bronchoscopy suites.

By Product Type Insights

The EBUS Bronchoscopes Segment Dominated the Market With 39% in 2025

The EBUS bronchoscopes segment accounted for the highest revenue share of 39% of the U.S. endobronchial ultrasound biopsy market in 2025, driven by hospitals continuing to replace conventional bronchoscopes with ultrasound-enabled systems. Increased bronchoscopy procedure volumes also sustained equipment demand. Advanced visualization capabilities also improved clinician confidence.

The biopsy needles segment held the second-largest share of 27% of the market in 2025 and is expected to show the highest growth with a CAGR of 9.6% during the forecast period, due to growing procedural frequency, which increases recurring needle consumption. Improved tissue acquisition for molecular testing also boosts their adoption. Single-use sterile designs also strengthen purchasing trends.

The ultrasound processors & imaging systems segment held 21% of the U.S. endobronchial ultrasound biopsy market share in 2025, driven by integrated imaging platforms, which improve workflow efficiency in pulmonary departments. Demand for real-time imaging also supports technology upgrades. Academic centers also expand advanced imaging infrastructure.

The accessories segment held 13% of the market share in 2025, as supporting accessories enhance procedural flexibility and sampling precision. Expansion of bronchoscopy labs also increases accessory utilization. Manufacturers are also introducing disposable accessory portfolios for infection control.

By Application Insights

The Lung Cancer Diagnosis & Staging Segment Dominated the Market With 49% in 2025

The lung cancer diagnosis & staging segment held a major revenue share of 49% of the U.S. endobronchial ultrasound biopsy market in 2025, due to growth in the incidence of lung cancer, which increased demand for minimally invasive diagnostics. Precision oncology also requires accurate nodal staging. National screening initiatives also support earlier detection rates.

The mediastinal lymph node assessment segment held the second-largest share of 19% of the market in 2025, as physicians are increasingly preferring EBUS over surgical mediastinoscopy. Improved diagnostic sensitivity also enhances their adoption. A growing pulmonary disease burden also supports procedure growth.

The peripheral pulmonary lesion diagnosis segment held 12% of the U.S. endobronchial ultrasound biopsy market share in 2025 and is expected to expand rapidly with a CAGR of 11.80% during the forecast period, due to increasing CT screening, which detects more peripheral lung nodules. Navigation-assisted EBUS also improves lesion localization efficiency. Robotic bronchoscopy integration also accelerates their adoption.

The pulmonary infection diagnosis segment held 11% of the market share in 2025, as infectious pulmonary diseases require accurate tissue and fluid sampling. Hospitals are also adopting EBUS for complex respiratory infections. Immunocompromised patient populations also increase diagnostic demand.

By End User Insights

The Hospitals Segment Dominated the Market With 62% in 2025

The hospitals segment contributed the biggest revenue share of 62% of the U.S. endobronchial ultrasound biopsy market in 2025, as large hospitals maintained advanced bronchoscopy infrastructure. High patient inflow also supported procedural volumes. Multidisciplinary oncology programs also accelerated technology procurement.

The specialty clinics segment held the second-largest share of 17% of the market in 2025 and is expected to gain the highest share with a CAGR of 10.60% during the forecast period, as specialized pulmonology clinics increasingly invest in minimally invasive diagnostics. Faster patient turnaround also improves operational scalability. Expanding private pulmonary networks also fuels market penetration.

The ambulatory surgical centers segment held 14% of the U.S. endobronchial ultrasound biopsy market share in 2025, due to a shift toward outpatient pulmonary procedures, which increases EBUS biopsy utilization. Lower operational costs also improve procedural efficiency. Favorable reimbursement also encourages ASC adoption.

The diagnostic imaging centers segment held 7% of the market share in 2025, driven by imaging centers integrating diagnostic bronchoscopy services with radiology workflows. Demand for comprehensive pulmonary diagnostics also supports their growth. Collaborations with hospitals also expand referral networks.

Regional Insights

High Cancer Burden Drives U.S.

The U.S. endobronchial ultrasound biopsy market is expected to show considerable growth during the forecast period, due to the growth in lung cancer rates. A shift towards minimally invasive diagnostic procedures also increased their demand. The presence of advanced healthcare infrastructure also increased their use for personalized treatment development, which contributed to the market growth.

Market Value Chain Analysis

R&D

• The R&D of the U.S. endobronchial ultrasound biopsy focuses on the development of slimmer, high-angle bronchoscopes, high-yielding histological core needles, and AI-based diagnostics.
• Key players: Olympus Corporation, Boston Scientific Corporation, and Cook Medical.

Clinical Trials and Regulatory Approvals

• The diagnostics yield, procedural safety, device maneuverability, and tissue adequacy are evaluated in the clinical trials and regulatory approvals of the U.S. endobronchial ultrasound biopsy.
• Key players: Olympus Corporation, Boston Scientific Corporation, and Cook Medical.

Packaging and Serialization

• The packaging and sterilization of the U.S. endobronchial ultrasound biopsy involves the use of sterile, puncture-resistant Tyvek pouches complying with FDA Unique Device Identification (UDI) regulations and serialized 2D data matrix barcodes.
• Key players: Olympus Corporation, Boston Scientific Corporation, and Cook Medical.

Distribution to Hospitals, Pharmacies

• The large-scale national health logistics distributor and manufacturing giants are responsible for the distribution of the endobronchial ultrasound biopsy across the U.S. hospitals and pharmacies.
• Key players: Cardinal Health, Olympus Corporation, Boston Scientific Corporation.

Patient Support and Services

• Patient education programs, insurance navigation toolkits, and copay support services are provided in the patient support and services of the U.S. endobronchial ultrasound biopsy.
• Key players: Olympus Corporation, Boston Scientific Corporation, and Cook Medical.

Top Companies and Their Offerings in the Market

SWOT Analysis 

Strengths

• The endobronchial ultrasound biopsy is a minimally invasive procedure that increases its adoption rate.
• Their high diagnostic accuracy and real-time ultrasound guidance also increase their use.
• They also help in the diagnosis of mediastinal and hilar lymph nodes, driving their adoption.
• Their rapid diagnosis and lower risk of complications also increase their use in a wide range of applications.

Weaknesses

• High cost associated with the equipment and maintenance acts as the major weakness in the U.S. endobronchial ultrasound biopsy market, limiting its use.
• Shortage of skilled personnel also reduces their use.

Opportunities

• Growing lung cancer cases across the U.S. are increasing the use of endobronchial ultrasound biopsies.
• Increasing demand for minimally invasive approaches also increased their adoption.
• The growing shift towards precision medicines is also increasing their use.
• Expanding technological advancements are also driving their innovations.

Threats

• Stringent regulatory requirements slow down the development process of the endobronchial ultrasound biopsy in the U.S.
• Rapid technological advancements also reduce their innovations.

What are the Recent Developments in the Market?

• In May 2026, the EB-710US Ultrasound Bronchoscope, which is an endobronchial ultrasound (EBUS) solution, was launched by Fujifilm Healthcare Americas Corp. The product will offer improved imaging performance and streamline workflow for pulmonologists and healthcare systems.
• In July 2025, the next-generation EU-ME3 Ultrasound Processor was launched in the U.S. by the Olympus Corporation of the Americas, which is a global MedTech company. The product combines endobronchial and endoscopic ultrasound (EUS/EBUS) on a single workstation to offer improved functionality and image quality.

Segments Covered in the Report

By Procedure Type

• EBUS-TBNA (Endobronchial Ultrasound Guided Transbronchial Needle Aspiration)
  • Convex Probe EBUS-TBNA
  • Linear Probe EBUS-TBNA
• EBUS-GS (Guide Sheath)
  • Radial Probe EBUS-GS
  • Ultrathin Bronchoscope Guided EBUS-GS
• Combined EBUS Procedures
  • EBUS + Bronchoscopy
  • EBUS + Electromagnetic Navigation Bronchoscopy
  • EBUS + Robotic Bronchoscopy

By Product Type

• EBUS Bronchoscopes
  • Convex Probe Bronchoscopes
  • Radial Probe Bronchoscopes
  • Ultrathin Bronchoscopes
• Ultrasound Processors & Imaging Systems
  • Dedicated Ultrasound Consoles
  • Integrated Imaging Platforms
• Biopsy Needles
  • 19G Needles
  • 21G Needles
  • 22G Needles
  • 25G Needles
• Accessories
  • Guide Sheaths
  • Balloon Catheters
  • Cytology Brushes
  • Forceps
  • Suction & Aspiration Devices

By Application

• Lung Cancer Diagnosis & Staging
  • Non-Small Cell Lung Cancer
  • Small Cell Lung Cancer
• Mediastinal Lymph Node Assessment
• Pulmonary Infection Diagnosis
  • Tuberculosis
  • Fungal Infections
  • Bacterial Infections
• Inflammatory Diseases
  • Sarcoidosis
  • Granulomatous Diseases
• Peripheral Pulmonary Lesion Diagnosis

By End User

• Hospitals
  • Academic Medical Centers
  • Community Hospitals
  • Specialized Pulmonary Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
  • Pulmonology Clinics
  • Oncology Clinics
• Diagnostic Imaging Centers

By Patient Type

• Adult
  • Age 18–44
  • Age 45–64
  • Age 65+
• Pediatric

By Technology

• Convex Probe EBUS
• Radial Probe EBUS
• Hybrid Navigation EBUS
• Robotic-Assisted EBUS
• AI-Integrated EBUS Imaging

By Biopsy Needle Size

• 19G
• 21G
• 22G
• 25G

By Imaging Modality Integration

• Fluoroscopy-Assisted EBUS
• CT-Assisted Navigation EBUS
• Electromagnetic Navigation Integrated EBUS
• Robotic Imaging Integrated EBUS